Search 

Additional $0.5-1M to close seed round

Thetis has discovered and is in the early stages of developing several compounds in the omega-3 arena that are quite differentiated from existing agents based on its proprietary HEALER Technology. 

• TP-252 is an ionic derivative of eicosapentaenoic acid that delivers EPA with remarkable bioavailability in animal models. Unlike anything known in the omega-3 arena, TP-252 is a solid, stable, free-flowing drug substance that is suitable for tablet formulations and for potential use in fixed dose combination products with statins.
• TP-113 (bis-metformin glutamate DHA) is a novel oral agent for treatment of T2DM as a 2nd generation metformin product with substantial differentiating pharmacological attributes and intellectual property protection. Its PPP targets significant HbA1c reduction as its primary clinical endpoint with enhanced pharmacological benefits that include insulin resistance resolution, multiple mechanistic effects on hepatic gluconeogenesis that could translate into lower metformin dosing requirements, and reduced serum triglyceride (TG) levels.
• TP-352, an ionic derivative of docosahexaenoic acid that delivers DHA with remarkable bioavailability in animal models, has prospects for treatment of NASH based on the anti-fibrotic, metabolic and TG lowering effects of DHA.
• TP-110 (bis-metformin glutamate EPA) has prospects as a first in class agent for treatment of PCOS based on the clinically established effects of its active moeties for ovulation restoration, reduced insulin resistance and enhanced anti-androgenic effects.  
  

HEALER Technology applied to already approved APIs with established safety records.

$25 million to fund TP-113 through Phase IIa

INDs can be opened on lead candidates within 12 months due to non-clinical safety efficiencies based on prototype candidate already vetted by FDA

Connecticut Innovations and Angel Investors

Issued patents (US8765811, US8993124, US8901107) and non-provisional patent applications under petition to make special 

• TP-113 preclinical studies in mice showing PDX formation
• IND allowance establishing non-clinical safety of Thetis compounds
• Extensive rodent pharmacokinetic studies demonstrating unique PK properties
• Pre-formulation feasibility studies completed on lead candidates
• Issued composition of matter patents on metformin compounds (TP-113/110)

Frank Sciavolino, PhD, Chief Scientific Officer

• former Pfizer R&D executive (Zithromax) and in-licensing (Celebrex)
• PhD, Organic Chemistry, University of Michigan
• Over 30 issued patents

Gary Mathias, MBA, Chief Financial Officer

• Over 25 years as healthcare investment banking and entrepreneur
• Former SVP, GE Equity, Healthcare
• MBA, Yale University; BA Economics, Harvard College

Alexander Fleming, MD, Senior Clinical & Regulatory Officer

• Former supervisory physician, DMEP, FDA
• Expert in metabolic disease
• MD, Board Certified, Endocrinology, Emory University

Andre Marette, PhD, Lead Investigator and Scientific Advisor

• Professor of Medicine, Institute for Heart & Lung Research, Laval University
• Pfizer Research Chair, Pathogenesis of Insulin Resistance and CVD
• Recent publication on PDX effect on insulin resistance (Nat. Med. 5/11/2014)

Michael Van Zandt, PhD, Director, Discovery Chemistry

• Former Director, Institute for Pharmaceutical Discovery (1996-2012)
• PhD, Organic Chemistry, Wayne State University

Robert Lipper, PhD, Technical Consultant, Formulation

• VP, Biopharmaceutics, BMS (1984-2008)
• PhD, Pharmaceutical Chemistry, University of Michigan

Mehar Manku, PhD, Scientific Advisory

• former Chief Scientific Officer, Amarin Corp.
• Executive editor, PLEFAs
• Inventory on 61 patents in polyunsaturated fatty acids